STOCK TITAN

SeaStar Medical Holding Corporation - $ICU STOCK NEWS

Welcome to our dedicated page for SeaStar Medical Holding Corporation news (Ticker: $ICU), a resource for investors and traders seeking the latest updates and insights on SeaStar Medical Holding Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SeaStar Medical Holding Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SeaStar Medical Holding Corporation's position in the market.

Rhea-AI Summary
SeaStar Medical announces successful treatment of critically ill children with its Selective Cytopheretic Device for children (SCD-PED)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
Rhea-AI Summary
SeaStar Medical Holding Corporation to hold business update conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
none
-
Rhea-AI Summary
SeaStar Medical Holding Corporation (Nasdaq: ICU) reports financial results for the three and six months ended June 30, 2023, and provides a business update on the development of their proprietary solutions to reduce the consequences of hyperinflammation on vital organs. The company is actively enrolling patients in a pivotal trial for their patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill adults with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT). They are also working on qualifying additional medical centers to join the trial and expect to provide periodic updates on site activation and patient enrollment. SeaStar Medical CEO, Eric Schlorff, highlighted the differences between their adult and pediatric AKI programs, including the FDA pathways for approval and the proprietary characteristics between the pediatric SCD-PED and the adult SCD-ADULT devices. The company also mentioned the addressable adult AKI patient population of approximately 200,000 per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.25%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.09%
Tags
-
Rhea-AI Summary
SeaStar Medical Holding Corporation's CEO, Eric Schlorff, will present a company overview at the JMP Securities Life Sciences Conference on May 16, 2023. The conference will be held at the New York Hilton Midtown.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.69%
Tags
conferences
-
Rhea-AI Summary
SeaStar Medical Holding Corporation receives letter from FDA regarding HDE application for pediatric Selective Cytopheretic Device
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.69%
Tags
none
SeaStar Medical Holding Corporation

Nasdaq:ICU

ICU Rankings

ICU Stock Data

33.38M
35.55M
17.45%
1.44%
5.51%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
DENVER